HR

17.43

-1.75%↓

WDP

22.38

-0.09%↓

GFC

66.1

-0.53%↓

SLG

38.96

-1.49%↓

COVH.FR

22.3

+0.9%↑

HR

17.43

-1.75%↓

WDP

22.38

-0.09%↓

GFC

66.1

-0.53%↓

SLG

38.96

-1.49%↓

COVH.FR

22.3

+0.9%↑

HR

17.43

-1.75%↓

WDP

22.38

-0.09%↓

GFC

66.1

-0.53%↓

SLG

38.96

-1.49%↓

COVH.FR

22.3

+0.9%↑

HR

17.43

-1.75%↓

WDP

22.38

-0.09%↓

GFC

66.1

-0.53%↓

SLG

38.96

-1.49%↓

COVH.FR

22.3

+0.9%↑

HR

17.43

-1.75%↓

WDP

22.38

-0.09%↓

GFC

66.1

-0.53%↓

SLG

38.96

-1.49%↓

COVH.FR

22.3

+0.9%↑

Search

Covivio

Fechado

SetorImobiliário

51.8 -1.71

Visão Geral

Variação de preço das ações

24h

Atual

Mín

51.6

Máximo

52.65

Indicadores-chave

By Trading Economics

Rendimento

341M

Vendas

-387M

338M

P/E

Médio do Setor

15.239

67.236

Rendimento de Dividendos

6.79

Margem de lucro

47.09

Funcionários

958

EBITDA

-18M

422M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+15.46% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

6.79%

6.64%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

332M

6.4B

Abertura anterior

53.51

Fecho anterior

51.8

Sentimento de Notícias

By Acuity

25%

75%

23 / 167 Ranking em Real estate

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Covivio Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de mar. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 de mar. de 2026, 22:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 de mar. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 de mar. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 de mar. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Global Equities Roundup: Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 de mar. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 de mar. de 2026, 22:23 UTC

Conversa de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 de mar. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 de mar. de 2026, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 de mar. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 de mar. de 2026, 22:08 UTC

Conversa de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 de mar. de 2026, 21:10 UTC

Notícias Principais

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Notícias Principais

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Covivio Previsão

Preço-alvo

By TipRanks

15.46% parte superior

Previsão para 12 meses

Média 62 EUR  15.46%

Máximo 66 EUR

Mínimo 58 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Covivio - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

2 ratings

0

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

49.2 / 49.62Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

23 / 167 Ranking em Imobiliário

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Covivio

Thanks to its partnering history, its real estate expertise and its European culture, Covivio is inventing today's user experience and designing tomorrow's city. A preferred real estate player at the European level, Covivio is close to its end users, capturing their aspirations, combining work, travel, living, and co-inventing vibrant spaces. A benchmark in the European real estate market with "23.0 bn in assets, Covivio offers support to companies, hotel brands and territories in their pursuit for attractiveness, transformation and responsible performance. Build sustainable relationships and well-being, is the Covivio's Purpose who expresses its role as a responsible real estate operator to all its stakeholders: customers, shareholders and financial partners, internal teams, local authorities but also to future generations and the planet. Furthermore, its living, dynamic approach opens up exciting project and career prospects for its teams. Covivio's shares are listed in the Euronext Paris A compartment (FR0000064578 - COV), are admitted to trading on the SRD, and are included in the composition of the MSCI, SBF 120, Euronext IEIF "SIIC France" and CAC Mid100 indices, in the "EPRA" and "GPR 250" benchmark European real estate indices, and in the ESG FTSE4 Good, CAC SBT 1.5°C, DJSI World & Europe, Euronext Vigeo (World 120, Eurozone 120, Europe 120 and France 20), Euronext CDP Environment France EW, ISS ESG, Ethibel and Gaïa ethical indices and also holds the following awards and ratings: CDP (A), GRESB (88/100, 5-Star), ISS-ESG (B-) and MSCI (AAA).
help-icon Live chat